GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anixa Biosciences Inc (NAS:ANIX) » Definitions » PB Ratio

ANIX (Anixa Biosciences) PB Ratio : 4.64 (As of Apr. 05, 2025)


View and export this data going back to 1989. Start your Free Trial

What is Anixa Biosciences PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2025-04-05), Anixa Biosciences's share price is $2.57. Anixa Biosciences's Book Value per Share for the quarter that ended in Jan. 2025 was $0.55. Hence, Anixa Biosciences's PB Ratio of today is 4.64.

Warning Sign:

Anixa Biosciences Inc stock PB Ratio (=4.64) is close to 1-year high of 4.72.

The historical rank and industry rank for Anixa Biosciences's PB Ratio or its related term are showing as below:

ANIX' s PB Ratio Range Over the Past 10 Years
Min: 1.74   Med: 5.49   Max: 54.06
Current: 4.64

During the past 13 years, Anixa Biosciences's highest PB Ratio was 54.06. The lowest was 1.74. And the median was 5.49.

ANIX's PB Ratio is ranked worse than
75.64% of 1285 companies
in the Biotechnology industry
Industry Median: 2.22 vs ANIX: 4.64

During the past 12 months, Anixa Biosciences's average Book Value Per Share Growth Rate was -28.50% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -19.20% per year. During the past 5 years, the average Book Value Per Share Growth Rate was 20.40% per year. During the past 10 years, the average Book Value Per Share Growth Rate was 11.90% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Anixa Biosciences was 60.20% per year. The lowest was -36.50% per year. And the median was 3.50% per year.

Back to Basics: PB Ratio


Anixa Biosciences PB Ratio Historical Data

The historical data trend for Anixa Biosciences's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anixa Biosciences PB Ratio Chart

Anixa Biosciences Annual Data
Trend Oct15 Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23 Oct24
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.71 4.05 5.96 4.05 5.64

Anixa Biosciences Quarterly Data
Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.86 4.02 4.90 5.64 5.23

Competitive Comparison of Anixa Biosciences's PB Ratio

For the Biotechnology subindustry, Anixa Biosciences's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anixa Biosciences's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Anixa Biosciences's PB Ratio distribution charts can be found below:

* The bar in red indicates where Anixa Biosciences's PB Ratio falls into.


;
;

Anixa Biosciences PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Anixa Biosciences's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Jan. 2025)
=2.57/0.554
=4.64

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Anixa Biosciences  (NAS:ANIX) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Anixa Biosciences PB Ratio Related Terms

Thank you for viewing the detailed overview of Anixa Biosciences's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Anixa Biosciences Business Description

Traded in Other Exchanges
Address
3150 Almaden Expressway, Suite 250, San Jose, CA, USA, 95118
Anixa Biosciences Inc a cancer-focused biotechnology company, develops vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.
Executives
Arnold M Baskies director 1235 SEQUOIA ROAD, CHERRY HILL NJ 08003
Titterton Lewis H Jr director 6 AUTUMN LANE, SARATOGA SPRINGS NY 12866
Amit Kumar director, officer: Chief Executive Officer C/O ACACIA RESEARCH CORPORATION, 500 NEWPORT CENTER DRIVE, 7TH FLOOR, NEWPORT BEACH CA 92660
Michael Catelani officer: COO & CFO 12100 WILSHIRE BOULEVARD, SUITE 1275, LOS ANGELES CA 90025
Emily Gottschalk director 3150 ALMADEN EXPRESSWAY, SUITE 250, SAN JOSE CA 95118
John J Monahan director
David Cavalier director C/O AEOLUS PHARMACEUTICALS, INC., 23811 INVERNESS PLACE, LAGUNA NIGUEL CA 92677
Richard H Williams director C/O QUOKKA SPORTS INC, 525 BRANNAN ST GROUND FL, SAN FRANCISCO CA 94108
Dale Fox director 929 NOWITA PLACE, VENICE CA 90291
Andrea Belz director 1011 ALTA VISTA DRIVE, ALTADENA CA 91001
Tisha Stender officer: Chief Operating Officer 900 WALT WHITMAN ROAD, MELVILLE NY 11747
Robert Andrew Berman officer: President and CEO C/O ITUS CORPORATION, 12100 WILSHIRE BOULEVARD, SUITE 1275, LOS ANGELES CA 90025
John H. Roop officer: Sr. Vice President-Engineering C/O COPYTELE, INC., 900 WALT WHITMAN ROAD, MELVILLE NY 11747
Bruce F Johnson director 20 S. WACKER DR, CHICAGO IL 60606
Kent B. Williams director C/O COPYTELE INC., 900 WALT WHITMAN ROAD, MELVILLE NY 11747